|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||||||||
| CURRENT ASSETS | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Prepaid Clinical trial expenses | ||||||||||||||||||||
| Available for sale debt security | ||||||||||||||||||||
| Digital assets | ||||||||||||||||||||
| Prepaid expenses and other current assets | ||||||||||||||||||||
| TOTAL CURRENT ASSETS | ||||||||||||||||||||
| Equity method investment | ||||||||||||||||||||
| Fixed assets, net of accumulated depreciation | ||||||||||||||||||||
| Yuma Partnership investments | ||||||||||||||||||||
| TOTAL ASSETS | ||||||||||||||||||||
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||||||||||||||
| CURRENT LIABILITIES | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Accrued expenses | ||||||||||||||||||||
| Accrued Series B Convertible Preferred payments payable | ||||||||||||||||||||
| Accrued Convertible Preferred payments payable | ||||||||||||||||||||
| TOTAL CURRENT LIABILITIES | ||||||||||||||||||||
| Warrant liability | ||||||||||||||||||||
| Derivative liability | ||||||||||||||||||||
| TOTAL LIABILITIES | ||||||||||||||||||||
| Convertible redeemable preferred stock, value | ||||||||||||||||||||
| Series B Convertible Redeemable Preferred Stock | ||||||||||||||||||||
| Series C Convertible Redeemable Preferred Stock | ||||||||||||||||||||
| Series D convertible redeemable preferred stock | ||||||||||||||||||||
| Series C Convertible Preferred Stock | ||||||||||||||||||||
| Series D Convertible Preferred Stock | ||||||||||||||||||||
| Series E Convertible Preferred Stock | ||||||||||||||||||||
| Total convertible redeemable preferred stock, value | ||||||||||||||||||||
| STOCKHOLDERS' EQUITY | ||||||||||||||||||||
| Common stock - 150,000,000 shares authorized, $0.0001 par value; 7,473,112 shares issued and outstanding as of June 30, 2026 and 7,448,343 shares issued and outstanding as of December 31, 2025. | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Accumulated other comprehensive income | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| TOTAL STOCKHOLDERS' EQUITY | ||||||||||||||||||||
| TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||||||||||||||
Loading...
